Bolt Biotherapeutics Inc
BOLT6.140USD
+5.816+1800.93%
Close 06/09, 16:00（ET）Quotes delayed by 15 min
235.41MMarket Cap
LossP/E TTM
More Details of Bolt Biotherapeutics Inc Company
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Company Info
Company codeBOLT
Company nameBolt Biotherapeutics Inc
IPO dateFeb 05, 2021
Founded at2015
CEOMr. William P. (Willie) Quinn
Number of employees52
Security typeOrdinary Share
Fiscal year-endFeb 05
Address900 Chesapeake Drive
CityREDWOOD CITY
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94063
Phone16506659295
Websitehttps://boltbio.com/
Company codeBOLT
IPO dateFeb 05, 2021
Founded at2015
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. William P. (Willie) Quinn
Mr. William P. (Willie) Quinn
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
2.06K
--
Mr. Grant Yonehiro
Mr. Grant Yonehiro
Chief Operating Officer
Chief Operating Officer
446.00
--
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
60.00
--
Dr. Jakob Dupont, M.D.
Dr. Jakob Dupont, M.D.
Independent Director
Independent Director
--
--
Dr. Laura Berner
Dr. Laura Berner
Independent Director
Independent Director
--
--
Mr. Brian O'Callaghan
Mr. Brian O'Callaghan
Independent Director
Independent Director
--
--
Dr. Nicole Onetto, M.D.
Dr. Nicole Onetto, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. William P. (Willie) Quinn
Mr. William P. (Willie) Quinn
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
2.06K
--
Mr. Grant Yonehiro
Mr. Grant Yonehiro
Chief Operating Officer
Chief Operating Officer
446.00
--
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
60.00
--
Dr. Jakob Dupont, M.D.
Dr. Jakob Dupont, M.D.
Independent Director
Independent Director
--
--
Dr. Laura Berner
Dr. Laura Berner
Independent Director
Independent Director
--
--
Mr. Brian O'Callaghan
Mr. Brian O'Callaghan
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sat, May 17
Update time: Sat, May 17
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Tang Capital Management, LLC
9.94%
Vivo Capital, LLC
9.18%
Sofinnova Investments, Inc
7.18%
Pivotal Bioventure Partners Investment Advisor LLC
4.93%
The Vanguard Group, Inc.
3.05%
Other
65.70%
Shareholder Statistics
Shareholder
Proportion
Tang Capital Management, LLC
9.94%
Vivo Capital, LLC
9.18%
Sofinnova Investments, Inc
7.18%
Pivotal Bioventure Partners Investment Advisor LLC
4.93%
The Vanguard Group, Inc.
3.05%
Other
65.70%
Type
Shareholder
Proportion
Venture Capital
27.12%
Hedge Fund
12.51%
Investment Advisor/Hedge Fund
4.49%
Endowment Fund
1.88%
Corporation
1.63%
Investment Advisor
1.20%
Individual Investor
0.63%
Research Firm
0.06%
Other
50.48%
Institutional Shareholding
Update time: Mon, Feb 24
Update time: Mon, Feb 24
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
81
20.37M
53.13%
-2.73M
2024Q4
84
20.41M
53.33%
-2.94M
2024Q3
100
20.55M
53.71%
-13.67M
2024Q2
112
24.40M
63.99%
-9.89M
2024Q1
151
25.82M
67.70%
-11.61M
2023Q4
160
25.97M
68.41%
-12.06M
2023Q3
180
25.97M
68.42%
-15.51M
2023Q2
187
26.49M
70.05%
-14.41M
2023Q1
209
24.75M
65.45%
-14.17M
2022Q4
206
21.88M
58.13%
-16.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tang Capital Management, LLC
3.81M
9.94%
--
--
Dec 31, 2024
Vivo Capital, LLC
3.52M
9.18%
--
--
Dec 31, 2024
Sofinnova Investments, Inc
2.75M
7.18%
--
--
Dec 31, 2024
Pivotal Bioventure Partners Investment Advisor LLC
1.89M
4.93%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
1.07M
2.78%
--
--
Dec 31, 2024
Nan Fung Life Sciences
1.17M
3.04%
--
--
Dec 31, 2024
Samsara BioCapital, LLC
1.05M
2.74%
--
--
Dec 31, 2024
Stanford Management Company
719.55K
1.88%
--
--
Dec 31, 2024
Pfizer Inc
626.11K
1.63%
+626.11K
--
Dec 31, 2024
Hawkeye Capital Management, LLC
415.04K
1.08%
--
--
Sep 30, 2023
View more
Related ETFs
Update time: Fri, Jun 6
Update time: Fri, Jun 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
